Cancer Gene Therapy Market Size By Type [Gene Induced Immunotherapy (Cytokine Gene Delivery, Tumor Antigen Gene Delivery), Oncolytic Virotherapy (Adenoviruses, Lentiviruses, Retrovirus, Adeno Associated Virus, Herpes Simplex Virus, Alphavirus, Vaccinia Virus, Simian Virus), Gene Transfer/Gene Replacement (Naked/Plasmid Vectors, Electroporation, Sonoporation, Magnetofection, Gene Gun)], Industry Analysis Report, Regional Outlook (U.S., Canada, UK, Germany, China, Japan, Mexico, Brazil, South Africa, Saudi Arabia), Application Potential, Price Trends, Competitive Market Share & Forecast, 2016 - 2024

Cancer Gene Therapy Market size is expected to exceed USD 4.3 billion by 2024; as per a new research report by Global Market Insights, Inc.
 

Globally, rising cancer prevalence will increase demand for gene therapy as the effective personalized treatment choice.  According to WHO, cancer incidence is projected to rise by 50% to reach 15 million by the end of this decade. This alarming increase in number of patients necessitates this as a potential treatment approach addressing the growing global burden of the disease.
 

Increased adoption of emerging genomic technologies such as NGS and high density micro array coupled with favorable government initiatives will fuel global cancer gene therapy market size. For instance, CDC supports nationwide screening programs for control of breast, cervical and colorectal cancer among low-income women with little or no health insurance. However, high cost of development lack of reimbursement and regulatory processes will restrain industry growth.


Growing number of clinical trials and availability of wide range of genes and vectors used in these trials will enable emergence of new treatment modalities to help make cancer a manageable disease. By the end of 2012, the number of clinical trials crossed 1,800 worldwide.
 

Adenoviral vector remains as the most common oncology application due to its competent nuclear mechanism and low pathogenicity. It is widely used in replacement approaches, suicide and gene-based immunotherapy, and syndicate with chemotherapy and is anticipated to grow at 20% CAGR.
 

Retroviral vector-mediated gene transfer dominated the development by enabling the conversion of single stranded RNA into a double stranded DNA molecule, which steadily integrates into the target cell genome. These vectors are used to permanently modify the host cell nuclear genome and will register a robust growth of over 20%.
 

U.S. led the industry owing to increased R&D funding and other government initiatives. Growing number of biotech companies are engaging in R&D and clinical trials of gene therapy products. Increased demand for DNA vaccines and increasing interest of venture capitalists to invest in commercialization of gene therapies will trigger industry expansion.
 

China cancer gene therapy market size attributed to over 35% APAC revenue in 2015. With the launch of Gendicine and increasing healthcare expenditure and robust R&D facilities will enable industry growth.
 

Key insights from the report include:


U.S. cancer gene therapy market share accounted for over 95% regional revenue in 2015, with market size of USD 235 million and a forecast to grow at 20.9% CAGR.

UK was over USD 92.0 million in 2015, and will grow at 20.8% CAGR owing to increasing incidence of cancer and adoption of advanced treatment methods.

China market size was valued at USD 99.6 million in 2015 and growth expectations of 21% CAGR over the forecast years.

Key players include SiBiono, Altor Bioscience Corporation, Shanghai Sunway Biotech company limited, Amgen, BioCancell, OncoGeneX, Aduro Biotech, GlobeImmune, Inc., New Link Genetics., ZioPharm Oncology, MolMed, GENELUX, Gradalis, MultiVir.

The industry is highly fragmented and is dominated by several small biotech firms collectively accounting for over 80% of cancer gene therapy market pipeline. Major growth strategies adopted by these small firms include, technology transfer, licensing and commercialization deals, strategic collaborations and mergers and acquisitions to retain their industry position.



Global Market Insights has segmented the cancer gene therapy industry on the basis of therapy type, and region

Cancer Gene Therapy Market Type Analysis (Revenue, USD Million, 2012 - 2024)


Gene induced immunotherapy

Delivery of cytokine gene
Delivery of Tumor antigen gene


Oncolytic Virotherapy

Adenoviruses
Lentiviruses
Retrovirus
Adeno Associated Virus
Herpes Simplex Virus
Alphavirus
Vaccinia Virus
Simian Virus


Gene transfer / Gene replacement

Naked/Plasmid Vectors
Electroporation
Sonoporation
Magnetofection
Gene Gun




Cancer Gene Therapy Market Regional Analysis (Revenue, USD Million, 2012 - 2024)


North America

U.S.
Canada


Europe

Germany
UK
France
Spain
Italy
Russia
Poland


Asia Pacific

China
Japan
India
Australia
Malaysia
Indonesia  
Thailand


Latin America

Brazil
Mexico
Argentina


MEA


    South Africa Saudi Arabia Kenya Israel Egypt
Report Content

Chapter 1.    Methodology and Scope

1.1.    Research Methodology   

1.1.1.    Initial data exploration

1.1.2.    Statistical modeling and forecast

1.1.3.    Industry insights and validation

1.1.4.    Research scope & assumptions    

1.2.    Data Sources

Chapter 2.    Executive Summary

2.1.    Cancer genetics industry 360 degree synopsis, 2012 - 2024

2.1.1.    Business trends

2.1.2.    Regional trends

2.1.3.    Application trends

Chapter 3.    Cancer Gene Therapy Industry Insights

3.1.  Industry segmentation

3.2.  IIndustry Size and forecast, 2012 - 2024

3.3.  Industry Impact forces

3.3.1.    Growth drivers

3.3.1.1.    Technological advancements

3.3.1.2.    Increased adoption of nanotechnology

3.3.1.3.    Favorable government regulations

3.3.2.    Industry pitfalls & challenges

3.3.2.1.    High cost of cancer genetherapy

3.4.  Growth potential analysis

3.5.  Porter's analysis

3.6.  Key opportunities prioritized, 2015

3.7.  PESTEL analysis

3.8.  Regulatory Landscape

3.8.1.    U.S.

3.8.2.    EU

3.8.3.    China

3.9.   Scientific and Ethical issues in Gene Therapy

3.10. Competitive landscape, 2015

3.11.  Pipeline Analysis by cancer type

3.11.1.   Head and Neck Cancer Pipeline Analysis

3.11.2.   Breast Cancer Pipeline Analysis

3.11.3.   Gastro Intestinal Cancer Pipeline Analysis

3.11.4.   Gentiourinary Cancer Pipeline Analysis

3.11.5.   Gynecological Cancer Pipeline Analysis

3.11.6.   Haemotological Cancer Pipeline Analysis

3.11.7.   Neurologic Cancer Pipeline Analysis

3.11.8.   Respiratory Cancer Pipeline Analysis

3.11.9.   Skin Cancer Pipeline Analysis

Chapter 4.    Cancer Gene Therapy Insights    

4.1.    Cancer gene therapy market share by therapy, 2015 & 2024

4.2.    Gene Induced Immunotherapy

4.2.1.    Market estimates and forecast, 2012-2024 (USD Million)

4.2.2.    Delivery of cytokine gene

4.2.2.1. Market estimates and forecast, 2012-2024 (USD Million)

4.2.3.    Delivery of tumor antigen gene

4.2.3.1. Market estimates and forecast, 2012-2024 (USD Million)

4.3.    Oncolytic Virotherapy

4.3.1.    Market estimates and forecast, 2012-2024 (USD Million)

4.3.2.    Adenoviruses

4.3.2.1. Market estimates and forecast, 2012-2024 (USD Million)

4.3.3.    Lentiviruses

4.3.3.1. Market estimates and forecast, 2012-2024 (USD Million)

4.3.4.    Retrovirus

4.3.4.1. Market estimates and forecast, 2012-2024 (USD Million)

4.3.5.    Adeno Associated Virus

4.3.5.1. Market estimates and forecast, 2012-2024 (USD Million)

4.3.6.    Herpes Simplex Virus

4.3.6.1. Market estimates and forecast, 2012-2024 (USD Million)

4.3.7.    Alphavirus

4.3.7.1. Market estimates and forecast, 2012-2024 (USD Million)

4.3.8.    Vaccinia Virus

4.3.8.1. Market estimates and forecast, 2012-2024 (USD Million)

4.3.9.    Simian Virus

4.3.9.1. Market estimates and forecast, 2012-2024 (USD Million)

4.3.10.  Others

4.3.10.1. Market estimates and forecast, 2012-2024 (USD Million)

4.4.    Gene transfer/ Gene replacement

4.4.1.    Market estimates and forecast, 2012-2024 (USD Million)

4.4.2.    Naked/Plasmid Vectors

4.4.2.1. Market estimates and forecast, 2012-2024 (USD Million)

4.4.3.    Electroporation

4.4.3.1. Market estimates and forecast, 2012-2024 (USD Million)

4.4.4.    Sonoportion

4.4.4.1. Market estimates and forecast, 2012-2024 (USD Million)

4.4.5.    Magnetofection

4.4.5.1. Market estimates and forecast, 2012-2024 (USD Million)

4.4.6.    Gene Gun

4.4.6.1. Market estimates and forecast, 2012-2024 (USD Million)

Chapter 5.    Cancer Gene Therapy Regional Insights

5.1.    Cancer gene therapy market share by region, 2015 & 2024

5.2.    North America

5.2.1.    Market estimates by therapy, 2012 - 2024 (USD Million)

5.2.2.    U.S.

5.2.2.1. Market estimates by therapy, 2012 - 2024 (USD Million)

5.2.3.    Canada

5.2.3.1. Market estimates by therapy, 2012 - 2024 (USD Million)

5.3.    Europe

5.3.1.    Market estimates by therapy, 2012 - 2024 (USD Million)

5.3.2.    Germany

5.3.2.1. Market estimates by therapy, 2012 - 2024 (USD Million)

5.3.3.    UK

5.3.3.1. Market estimates by therapy, 2012 - 2024 (USD Million)

5.3.4.    France

5.3.4.1. Market estimates by therapy, 2012 - 2024 (USD Million)

5.3.5.    Spain

5.3.5.1. Market estimates by therapy, 2012 - 2024 (USD Million)

5.3.6.    Italy

5.3.6.1. Market estimates by therapy, 2012 - 2024 (USD Million)

5.3.7.    Russia

5.3.7.1. Market estimates by therapy, 2012 - 2024 (USD Million)

5.3.8.    Poland

5.3.8.1. Market estimates by therapy, 2012 - 2024 (USD Million)

5.4.    Asia Pacific

5.4.1.    Market estimates by therapy, 2012 - 2024 (USD Million)

5.4.2.    China

5.4.2.1. Market estimates by therapy, 2012 - 2024 (USD Million)

5.4.3.    Japan

5.4.3.1. Market estimates by therapy, 2012 - 2024 (USD Million)

5.4.4.    India

5.4.4.1. Market estimates by therapy, 2012 - 2024 (USD Million)

5.4.5.    Australia

5.4.5.1. Market estimates by therapy, 2012 - 2024 (USD Million)

5.4.6.    Malaysia

5.4.6.1. Market estimates by therapy, 2012 - 2024 (USD Million)

5.4.7.    Indonesia  

5.4.7.1. Market estimates by therapy, 2012 - 2024 (USD Million)

5.4.8.    Thailand

5.4.8.1. Market estimates by therapy, 2012 - 2024 (USD Million)

5.5.    Latin America

5.5.1.    Market estimates by therapy, 2012 - 2024 (USD Million)

5.5.2.    Argentina

5.5.2.1. Market estimates by therapy, 2012 - 2024 (USD Million)

5.5.3.    Brazil

5.5.3.1. Market estimates by therapy, 2012 - 2024 (USD Million)

5.5.4.    Mexico

5.5.4.1. Market estimates by therapy, 2012 - 2024 (USD Million)

5.6.    MEA

5.6.1.    Market estimates by therapy, 2012 - 2024 (USD Million)

5.6.2.    South Africa

5.6.2.1. Market estimates by therapy, 2012 - 2024 (USD Million)

5.6.3.    Saudi Arabia

5.6.3.1. Market estimates by therapy, 2012 - 2024 (USD Million)

5.6.4.    Kenya

5.6.4.1. Market estimates by therapy, 2012 - 2024 (USD Million)

5.6.5.    Israel

5.6.5.1. Market estimates by therapy, 2012 - 2024 (USD Million)

5.6.6.    Egypt

5.6.6.1. Market estimates by therapy, 2012 - 2024 (USD Million)

Chapter 6. Company Profiles   

6.1.    Sibiono Genetech

6.1.1.    Business Overview

6.1.2.    Financial Data

6.1.3.    Product Landscape 

6.1.4.    Strategic Outlook

6.2.    Shanghai Sunway Biotech Co., LTD

6.2.1.    Business Overview

6.2.2.    Financial Data

6.2.3.    Product Landscape 

6.2.4.    Strategic Outlook

6.3.    Human Stem Cell Institute

6.3.1.    Business Overview

6.3.2.    Financial Data

6.3.3.    Product Landscape 

6.3.4.    Strategic Outlook

6.4.    Altor Bioscience Corporation

6.4.1.    Business Overview

6.4.2.    Financial Data

6.4.3.    Product Landscape 

6.4.4.    Strategic Outlook

6.5.    Amgen

6.5.1.    Business Overview

6.5.2.    Financial Data

6.5.3.    Product Landscape 

6.5.4.    Strategic Outlook

6.6.    BioCancell

6.6.1.    Business Overview

6.6.2.    Financial Data

6.6.3.    Product Landscape 

6.6.4.    Strategic Outlook

6.7.    Aduro Biotech

6.7.1.    Business Overview

6.7.2.    Financial Data

6.7.3.    Product Landscape 

6.7.4.    Strategic Outlook

6.8.    OncoGeneX

6.8.1.    Business Overview

6.8.2.    Financial Data

6.8.3.    Product Landscape 

6.8.4.    Strategic Outlook

6.9.    Celsion

6.9.1.    Business Overview

6.9.2.    Financial Data

6.9.3.    Product Landscape 

6.9.4.    Strategic Outlook

6.10.    GlobeImmune, Inc

6.10.1.  Business Overview

6.10.2.  Financial Data

6.10.3.  Product Landscape 

6.10.4.  Strategic Outlook

6.11.    New Link Genetics

6.11.1.  Business Overview

6.11.2.  Financial Data

6.11.3.  Product Landscape 

6.11.4.  Strategic Outlook

6.12.    Immuno Frontier, Inc.

6.12.1.  Business Overview

6.12.2.  Financial Data

6.12.3.  Product Landscape 

6.12.4.  Strategic Outlook

6.13.    MolMed S.p.A

6.13.1.  Business Overview

6.13.2.  Financial Data

6.13.3.  Product Landscape 

6.13.4.  Strategic Outlook

6.14.    Advantagene

6.14.1.  Business Overview

6.14.2.  Financial Data

6.14.3.  Product Landscape 

6.14.4.  Strategic Outlook

6.15.    Sevion Therapeutics

6.15.1.  Business Overview

6.15.2.  Financial Data

6.15.3.  Product Landscape 

6.15.4.  Strategic Outlook

6.16.    ZioPharm Oncology

6.16.1.  Business Overview

6.16.2.  Financial Data

6.16.3.  Product Landscape 

6.16.4.  Strategic Outlook

6.17.    Gradalis

6.17.1.  Business Overview

6.17.2.  Financial Data

6.17.3.  Product Landscape 

6.17.4.  Strategic Outlook

6.18.    AstraZeneca

6.18.1.  Business Overview

6.18.2.  Financial Data

6.18.3.  Product Landscape 

6.18.4.  Strategic Outlook

6.19.    OncoSec Medical Incorporated

6.19.1.  Business Overview

6.19.2.  Financial Data

6.19.3.  Product Landscape 

6.19.4.  Strategic Outlook

6.20.    Jennerex Biotherapeutics, Inc.

6.20.1.  Business Overview

6.20.2.  Financial Data

6.20.3.  Product Landscape 

6.20.4.  Strategic Outlook

6.21.    Nova Rx Corporation

6.21.1.  Business Overview

6.21.2.  Financial Data

6.21.3.  Product Landscape 

6.21.4.  Strategic Outlook

Data Tables TABLE 1 Cancer Genetics industry 360 degree synopsis, 2012 - 2024 TABLE 2 Global cancer gene therapy market, by therapy, 2012 - 2024(USD Million) TABLE 3 Global biosensors market, by region, 2012 - 2024(USD Million) TABLE 4 Cancer genetics - Growth drivers TABLE 5 Cancer genetics - Industry Pitfalls and Challenges TABLE 6 North America cancer gene therapy market, by therapy, 2012-2024 TABLE 7 North America market, by gene induced immunotherapy, 2012-2024 TABLE 8 North America cancer gene therapy market, by oncolytic virotherapy, 2012-2024 TABLE 9 North America cancer gene therapy market, by gene transfer, 2012-2024 TABLE 10 U.S. cancer gene therapy market, by therapy, 2012-2024 TABLE 11 U.S. cancer gene therapy market, by gene induced immunotherapy, 2012-2024 TABLE 12 U.S. cancer gene therapy market, by oncolytic virotherapy, 2012-2024 TABLE 13 U.S. cancer gene therapy market, by oncolytic virotherapy, 2012-2024 TABLE 14 Canada cancer gene therapy market, by therapy, 2012-2024 TABLE 15 Canada cancer gene therapy market, by gene induced immunotherapy, 2012-2024 TABLE 16 Canada cancer gene therapy market, by oncolytic virotherapy, 2012-2024 TABLE 17 Canada cancer gene therapy market, by gene transfer, 2012-2024 TABLE 18 Europe cancer gene therapy market, by therapy, 2012-2024 TABLE 19 Europe cancer gene therapy market, by gene induced immunotherapy, 2012-2024 TABLE 20 Europe cancer gene therapy market, by oncolytic virotherapy, 2012-2024 TABLE 21 Europe cancer gene therapy market, by gene transfer, 2012-2024 TABLE 22 Germany cancer gene therapy market, by therapy, 2012-2024 TABLE 23 Germany cancer gene therapy market, by gene induced immunotherapy, 2012-2024 TABLE 24 Germany cancer gene therapy market, by oncolytic virotherapy, 2012-2024 TABLE 25 Germany cancer gene therapy market, by gene transfer, 2012-2024 TABLE 26 UK cancer gene therapy market, by therapy, 2012-2024 TABLE 27 UK cancer gene therapy market, by gene induced immunotherapy, 2012-2024 TABLE 28 UK cancer gene therapy market, by oncolytic virotherapy, 2012-2024 TABLE 29 UK cancer gene therapy market, by gene transfer, 2012-2024 TABLE 30 France cancer gene therapy market, by therapy, 2012-2024 TABLE 31 France cancer gene therapy market, by gene induced immunotherapy, 2012-2024 TABLE 32 France cancer gene therapy market, by oncolytic virotherapy, 2012-2024 TABLE 33 France cancer gene therapy market, by gene transfer, 2012-2024 TABLE 34 Spain cancer gene therapy market, by therapy, 2012-2024 TABLE 35 Spain cancer gene therapy market, by gene induced immunotherapy, 2012-2024 TABLE 36 Spain cancer gene therapy market, by oncolytic virotherapy, 2012-2024 TABLE 37 Spain cancer gene therapy market, by gene transfer, 2012-2024 TABLE 38 Italy cancer gene therapy market, by therapy, 2012-2024 TABLE 39 Italy cancer gene therapy market, by gene induced immunotherapy, 2012-2024 TABLE 40 Italy cancer gene therapy market, by oncolytic virotherapy, 2012-2024 TABLE 41 Italy cancer gene therapy market, by gene transfer, 2012-2024 TABLE 42 Russia cancer gene therapy market, by therapy, 2012-2024 TABLE 43 Russia cancer gene therapy market, by gene induced immunotherapy, 2012-2024 TABLE 44 Russia cancer gene therapy market, by oncolytic virotherapy, 2012-2024 TABLE 45 Russia cancer gene therapy market, by gene transfer, 2012-2024 TABLE 46 Poland cancer gene therapy market, by therapy, 2012-2024 TABLE 47 Poland cancer gene therapy market, by gene induced immunotherapy, 2012-2024 TABLE 48 Poland cancer gene therapy market, by oncolytic virotherapy, 2012-2024 TABLE 49 Poland cancer gene therapy market, by gene transfer, 2012-2024 TABLE 50 Asia Pacific cancer gene therapy market, by therapy, 2012-2024 TABLE 51 Asia Pacific cancer gene therapy market, by gene induced immunotherapy, 2012-2024 TABLE 52 Asia Pacific cancer gene therapy market, by oncolytic virotherapy, 2012-2024 TABLE 53 Asia Pacific cancer gene therapy market, by gene transfer, 2012-2024 TABLE 54 China cancer gene therapy market, by therapy, 2012-2024 TABLE 55 China cancer gene therapy market, by gene induced immunotherapy, 2012-2024 TABLE 56 China cancer gene therapy market, by oncolytic virotherapy, 2012-2024 TABLE 57 China cancer gene therapy market, by gene transfer, 2012-2024 TABLE 58 Japan cancer gene therapy market, by therapy, 2012-2024 TABLE 59 Japan cancer gene therapy market, by gene induced immunotherapy, 2012-2024 TABLE 60 Japan cancer gene therapy market, by oncolytic virotherapy, 2012-2024 TABLE 61 Japan cancer gene therapy market, by gene transfer, 2012-2024 TABLE 62 India cancer gene therapy market, by therapy, 2012-2024 TABLE 63 India cancer gene therapy market, by gene induced immunotherapy, 2012-2024 TABLE 64 India cancer gene therapy market, by oncolytic virotherapy, 2012-2024 TABLE 65 India cancer gene therapy market, by gene transfer, 2012-2024 TABLE 66 Australia cancer gene therapy market, by therapy, 2012-2024 TABLE 67 Australia cancer gene therapy market, by gene induced immunotherapy, 2012-2024 TABLE 68 Australia cancer gene therapy market, by oncolytic virotherapy, 2012-2024 TABLE 69 Australia cancer gene therapy market, by gene transfer, 2012-2024 TABLE 70 Malaysia cancer gene therapy market, by therapy, 2012-2024 TABLE 71 Malaysia cancer gene therapy market, by gene induced immunotherapy, 2012-2024 TABLE 72 Malaysia cancer gene therapy market, by oncolytic virotherapy, 2012-2024 TABLE 73 Malaysia cancer gene therapy market, by gene transfer, 2012-2024 TABLE 74 Indonesia cancer gene therapy market, by therapy, 2012-2024 TABLE 75 Indonesia cancer gene therapy market, by gene induced immunotherapy, 2012-2024 TABLE 76 Indonesia cancer gene therapy market, by oncolytic virotherapy, 2012-2024 TABLE 77 Indonesia cancer gene therapy market, by gene transfer, 2012-2024 TABLE 78 Thailand cancer gene therapy market, by therapy, 2012-2024 TABLE 79 Thailand cancer gene therapy market, by gene induced immunotherapy, 2012-2024 TABLE 80 Thailand cancer gene therapy market, by oncolytic virotherapy, 2012-2024 TABLE 81 Thailand cancer gene therapy market, by gene transfer, 2012-2024 TABLE 82 Latin America cancer gene therapy market, by therapy, 2012-2024 TABLE 83 Latin America cancer gene therapy market, by gene induced immunotherapy, 2012-2024 TABLE 84 Latin America cancer gene therapy market, by oncolytic virotherapy, 2012-2024 TABLE 85 Latin America cancer gene therapy market, by gene transfer, 2012-2024 TABLE 86 Argentina cancer gene therapy market, by therapy, 2012-2024 TABLE 87 Argentina cancer gene therapy market, by gene induced immunotherapy, 2012-2024 TABLE 88 Argentina cancer gene therapy market, by oncolytic virotherapy, 2012-2024 TABLE 89 Argentina cancer gene therapy market, by gene transfer, 2012-2024 TABLE 90 Brazil cancer gene therapy market, by therapy, 2012-2024 TABLE 91 Brazil cancer gene therapy market, by gene induced immunotherapy, 2012-2024 TABLE 92 Brazil cancer gene therapy market, by oncolytic virotherapy, 2012-2024 TABLE 93 Brazil cancer gene therapy market, by gene transfer, 2012-2024 TABLE 94 Mexico cancer gene therapy market, by therapy, 2012-2024 TABLE 95 Mexico cancer gene therapy market, by gene induced immunotherapy, 2012-2024 TABLE 96 Mexico cancer gene therapy market, by oncolytic virotherapy, 2012-2024 TABLE 97 Mexico cancer gene therapy market, by gene transfer, 2012-2024 TABLE 98 Mexico cancer gene therapy market, by therapy, 2012-2024 TABLE 99 Mexico cancer gene therapy market, by gene induced immunotherapy, 2012-2024 TABLE 100 Mexico cancer gene therapy market, by oncolytic virotherapy, 2012-2024 TABLE 101 Mexico cancer gene therapy market, by gene transfer, 2012-2024 TABLE 102 MEA cancer gene therapy market, by therapy, 2012-2024 TABLE 103 MEA cancer gene therapy market, by gene induced immunotherapy, 2012-2024 TABLE 104 MEA cancer gene therapy market, by oncolytic virotherapy, 2012-2024 TABLE 105 MEA cancer gene therapy market, by gene transfer, 2012-2024 TABLE 106 South Africa cancer gene therapy market, by therapy, 2012-2024 TABLE 107 South Africa cancer gene therapy market, by gene induced immunotherapy, 2012-2024 TABLE 108 South Africa cancer gene therapy market, by oncolytic virotherapy, 2012-2024 TABLE 109 South Africa cancer gene therapy market, by gene transfer, 2012-2024 TABLE 110 Saudi Arabia cancer gene therapy market, by therapy, 2012-2024 TABLE 111 Saudi Arabia cancer gene therapy market, by gene induced immunotherapy, 2012-2024 TABLE 112 Saudi Arabia cancer gene therapy market, by oncolytic virotherapy, 2012-2024 TABLE 113 Saudi Arabia cancer gene therapy market, by gene transfer, 2012-2024 TABLE 114 Kenya cancer gene therapy market, by therapy, 2012-2024 TABLE 115 Kenya cancer gene therapy market, by gene induced immunotherapy, 2012-2024 TABLE 116 Kenya cancer gene therapy market, by oncolytic virotherapy, 2012-2024 TABLE 117 Kenya cancer gene therapy market, by gene transfer, 2012-2024 TABLE 118 Israel cancer gene therapy market, by therapy, 2012-2024 TABLE 119 Israel cancer gene therapy market, by gene induced immunotherapy, 2012-2024 TABLE 120 Israel cancer gene therapy market, by oncolytic virotherapy, 2012-2024 TABLE 121 Israel cancer gene therapy market, by gene transfer, 2012-2024 TABLE 122 Egypt cancer gene therapy market, by therapy, 2012-2024 TABLE 123 Egypt cancer gene therapy market, by gene induced immunotherapy, 2012-2024 TABLE 124 Egypt cancer gene therapy market, by oncolytic virotherapy, 2012-2024 TABLE 125 Egypt cancer gene therapy market, by gene transfer, 2012-2024 Charts & Figures FIG. 1 Industry Segmentation FIG. 2 Global cancer gene therapy market, 2012-2024 (USD Million) FIG. 3 Industry Impact forces FIG. 4 Growth potential analysis FIG. 5 Cancer gene therapy market Porter's analysis FIG. 6 Cancer gene therapy market PESTEL analysis

Name*
Email ID*
Company*
Phone (With Country Code)*
What is/are your question(s)?:

Other Reports by Global Market Insights, Inc.

U.S. Direct-to-Consumer Genetic Testing Market Size By Test Type (Carrier Testing, Predictive Testing, Ancestry & Relationship Testing, Nutrigenomics Testing), By Technology (Targeted Analysis, Single Nucleotide Polymorphism (SNP) Chips, Whole Genome Sequencing (WGS)), Industry Analysis Report, Application Potential, Competitive Market Share & Forecast, 2019 - 2025

U.S. Direct-To-Consumer Genetic Testing Market is expected to exceed USD 850 million by 2025. Increasing public awareness pertaining to availability of DTC genetic testing kits will be a high impact rendering factor for the U.S. DTC genetic testing m...

New Pharmaceuticals and Healthcare Reports

Publisher: Global Market Insights, Inc. 105 Pages